Comparing treatment strategies for heart failure: a real-world analysis of adding ARNI or SGLT2i to older GDMT

被引：0
|
作者：
Amornritvanich, P. [1 ]
Numthavaj, P. [1 ]
Anothaisintawee, T. [1 ]
Tansawet, A. [2 ]
Thakkinstian, A. [1 ]
机构：
[1] Mahidol Univ, Ramathibodi Hosp, Bangkok, Thailand
[2] Navamindradhiraj Univ, Fac Med Vajira Hosp, Dept Surg, Bangkok, Thailand
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷
关键词：
D O I：
10.1093/eurheartj/ehae666.1221
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ECHOCARDIOGRAPHIC FINDING BETWEEN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION IN TREATMENT WITH ARNI AND SGLT2I
    Ceci, Vincenzo
    Mazzeo, Pietro
    Ferrara, Salvatore
    Nardella, Luigi
    Tricarico, Lucia
    Alfieri, Simona
    Croella, Francesca
    Amatruda, Marco
    Granatiero, Michele
    D'alessandro, Damiano
    Di Nunno, Nicola
    Pugliese, Rosanna
    Noviello, Giulia
    Correale, Michele
    Stabile, Egenio
    Stabile, Eugenio
    Iacoviello, Massimo
    Di Biase, Matteo
    Brunetti, Natale D.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
  • [2] SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis
    Yan, Yuling
    Liu, Bin
    Du, Jun
    Wang, Jing
    Jing, Xiaodong
    Liu, Yajie
    Deng, Songbai
    Du, Jianlin
    She, Qiang
    ESC HEART FAILURE, 2021, 8 (03): : 2210 - 2219
  • [3] SGLT2i in CKD with high albuminuria: an observational real-world study
    Svensson, Maria K.
    Bodegard, Johan
    Thuresson, Marcus
    Ambery, Philip
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I263 - I264
  • [4] SGLT2i in CKD with high albuminuria: an observational real-world study
    Svensson, Maria K.
    Bodegard, Johan
    Thuresson, Marcus
    Ambery, Philip
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [5] Baseline characteristics and alterations after initiation of therapy with SGLT2i in a real-world heart failure with reduced ejection fraction population
    Stavrati, A.
    Polymeropoulos, K.
    Ioannidis, P.
    Kleitsioti, P.
    Lazaridis, P.
    Zarifis, J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 163 - 163
  • [6] Real-life introduction of SGLT2i during an hospitalization for heart failure
    Brisse, A.
    Huttin, O.
    Zannad, N.
    Girerd, N. Nicolas
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 304 - 304
  • [7] SGLT2i in heart failure with reduced ejection fraction: benefits in real life?
    Sanchez Gonzalez, V. Virtudes
    Flano-Lombardo, R.
    Esteve-Ruiz, I.
    Cortez, G.
    Aranda-Dios, A.
    Duran-Torralba, C.
    Rangel-Sousa, D.
    Sobrino-Marquez, J. M.
    Grande-Trillo, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 72 - 73
  • [8] Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 591 - 591
  • [9] Real world experience of SGLT2i in HFrEF patients
    Saharudin, S.
    Yen, C. H.
    Tan, S. L.
    Kaukiah, N. F.
    Yong, V. S.
    Liew, H. B.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 393
  • [10] SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series
    Zampieri, Mattia
    Argiro, Alessia
    Allinovi, Marco
    Perfetto, Federico
    Cappelli, Francesco
    INTERNAL AND EMERGENCY MEDICINE, 2022, 17 (04) : 1243 - 1245
12345